ZY News and Press, Zymergen Inc. From 06/02/22

Immix Biopharma (IMMX) +37%. Repare Therapeutics RPTX +28% on signing licensing deal with Repare Therapeutics for tumor candidate. Chewy CHWY +20% on Q1 results. UiPath PATH +12% on Q1 results. Blue Apron Holdings APRN +11% after launch of meal kits on ...

Gainers: Zymergen (ZY) +22%. Amyris (AMRS) +16%. Houston American Energy (HUSA) +14%. Livent (LTHM) +13%. TMC the metals company (TMC) +12%. Losers: Mesa Royalty Trust (MTR) -34%. For further details see: Livent and Amyris among Energy/Material gainers; Mesa Royalty Trust on l...

EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation system to scale Octant’s next-generation platform to develop...

- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS announces effectiveness of registration statem...

The stock for Zymergen Inc. has been in freefall since an initial recovery attempt following last year's disaster. The company will run out of cash in 2023 and prospects for viability remain murky. Of the many research and development projects underway, reconfigurable automation c...

Extremely ambitious objectives have fueled a relatively large market capitalization before the company has really achieved anything significant. Most synthetic biology companies appear to be taking similar approaches to product development and it is unclear whether Ginkgo really has a...

Zymergen, Inc. (ZY) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Carrie Mendivil - IR Jay Flatley - Acting CEO Ena Singh - CFO Conference Call Participants Matt Sykes - Goldman Sachs Steven Mah - Cowen Matt Larew - William Blair Rachel Vatnsdal - JPMorgan Pres...

Image source: The Motley Fool. Zymergen Inc. (NASDAQ: ZY) Q1 2022 Earnings Call May 12, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Zymergen Inc. (ZY) Q1 2022 Earnings Call Transcript

Zymergen press release (NASDAQ:ZY): Q1 GAAP EPS of -$0.70 beats by $0.05. Revenue of $4.79M (+28.1% Y/Y) beats by $1.45M. “Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to crea...

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the first quarter ended March 31, 2022. “Our mission at Zymergen is to partner wi...